Benjamin Ebert News Today

What started as a story about a gutter company leaving customers in the lurch led the NBC 5 Responds team to uncover a federal investigation into that...

Christopher Hourigan, director of the Fralin Biomedical Research Institute Cancer Research Center — D.C., was inducted this week into the American Society for

The link between long telomeres or cell clocks and long life is a tall tale

The longer a person’s telomeres, researchers found, the greater the risk of cancer and other disorders, challenging a popular hypothesis about the chromosomal roots of vitality.

Members of the campus community gathered last Wednesday to mark the anniversary and pay special tribute to Jim Craig.

The four inaugural recipients of the Lubin Family Foundation Scholar Award have been announced by Dana-Farber Cancer Institute and the Richard K. Lubin Family Foundation.

Kungl. Vetenskapsakademien: New knowledge about a cancer pharmaceutical led to the Sjöberg Prize MALMÖ, Sweden, Feb. 15, 2021 /PRNewswire/ -- Benjamin L. Ebert, USA, receives this years Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer. His discovery of the mechanism that promotes protein breakdown in cancer cells may be vitally important to the future development of new pharmaceuticals. The story of this pharmaceutical...

Benjamin L. Ebert, USA, receives this year's Sjöberg Prize, worth one million US dollars, for his research into how lenalidomide works as a treatment for blood cancer.

Date Time Dana-Farber Medical Oncology Chair receives Sjöberg Prize for cancer research Benjamin Ebert, MD, PhD, Chair of Medical Oncology at Dana-Farber Cancer Institute, George P. Canellos, MD, and Jean S. Canellos Professor of Medicine at Harvard Medical School, and Institute Member of Broad Institute of Harvard and MIT, has been awarded the Sjöberg Prize, an annual international prize in cancer research. The prize was awarded for Dr. Ebert’s discovery of the mode of action of lenalidomi...

CAR T cells are a breakthrough class of effective but often toxic cancer therapies To prevent overactivation, switchable CAR T cells were engineered that can be turned on and off with an approved, widely used cancer drug BOSTON - Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success in treating some advanced cancers, but whic...